MerLion Pharmaceuticals

Focus: MerLion Pharmaceuticals is a German-based antibacterial drug developer focused on Neurology and Infectious Diseases with a pipeline of early-stage fluoroquinolones and lipopeptides.

Neurology Infectious Diseases

Profile data last refreshed Yesterday · AI intelligence enriched 1w ago

Open Jobs

About MerLion Pharmaceuticals

AI assessmentNot Hiring

No open roles listed right now. Follow MerLion Pharmaceuticals to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

8 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Finafloxacin i.v. solution 200 mg

Healthy

Phase 1

Clinical Trials (1)

NCT01910883Safety and Tolerability of Single and Multiple Intravenous Doses of Finafloxacin in Healthy Subjects

Phase 1

Help build intelligence for MerLion Pharmaceuticals

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Focused pipeline in high-need antibacterial space with 8 active clinical programs targeting resistant infections (UTIs, pneumonia, H. pylori)
Early-stage company offers potential equity upside and hands-on involvement in drug development from Phase 1 through commercialization
Berlin location provides access to European biotech talent pool and regulatory pathways (EMA)

Watch Out For

Zero current job openings and no disclosed funding or revenue, indicating significant execution and financing risk
Portfolio heavily concentrated on Finafloxacin (5 of 8 programs), creating pipeline concentration risk if lead asset fails

Generated by Claude from MerLion Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

400 mg finafloxacin

Pharmacokinetic and Tolerability of Finafloxacin

Phase 1

Clinical Trials (1)

NCT01904162Effect of Age and Gender on the PK and Tolerability of Finafloxacin

Phase 1

Finafloxacin hydrochloride

Helicobacter Infections

Phase 1

Clinical Trials (1)

NCT00483158First Time in Man Study of Finafloxacin Hydrochloride

Phase 1